Navigation Links
MedThink Communications Retained by NanoBio Corporation
Date:9/4/2007

RALEIGH, N.C., Sept. 4 /PRNewswire/ -- MedThink Communications, an innovator in health care communications and public relations, has been retained by NanoBio Corporation to promote its novel technology that uses nano-sized particles to eradicate skin infections, without harming normal tissue.

MedThink will implement a scientifically based communications program that includes public relations, advocacy development and medical communications in order to advance NanoBio's lead products, two topical agents (NB-001 and NB-002) that safely treat cold sores and toenail fungus.

"The depth of our scientific expertise allows us to transform highly technical information into readily understandable messages that resonate with a company's key audiences," said Scott Goudy, partner at MedThink. "Our scientific staff works in tandem with the promotional and public relations teams to build a comprehensive, integrated communications program."

NanoBio's scientific platform is in various stages of testing for skin infections, shingles, eye infections, vaginitis, genital herpes, and mucosal vaccines against influenza and hepatitis B. The mucosal vaccines, delivered nasally, will carry antigens that serve to alert and rouse the immune system into action against each respective infection. In the future, NanoBio plans to apply its technology to other mucosal vaccines that may include tuberculosis, small pox, anthrax and other viral and bacterial diseases.

ABOUT MEDTHINK COMMUNICATIONS

MedThink Communications is an award-winning, full-service medical agency whose communication services capture the essence of your brand and transform it into compelling messages that inspire your target audiences. Our innovative approach to advertising, medical communications, public relations, media planning and placement, sales training and marketing consulting serves as the perfect complement to strengthen our health care partners' competitive edge. (http://www.medthink.com)

ABOUT NANOBIO

NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines, based on its patented NanoStat(TM) technology platform. Founded in 2000 as a spin-out from the Center for Biologic Nanotechnology at the University of Michigan, NanoBio's lead product candidates target treatments for herpes labialis (cold sores), onychomycosis (nail fungus) and mucosal vaccines for hepatitis B and influenza. The company's pipeline also includes products that target genital herpes, herpes zoster (shingles) and methicillin-resistant Staphylococcus aureus (MRSA).


'/>"/>
SOURCE MedThink Communications
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Physician and Patient relationship strained due to non-verbal communications
2. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
Breaking Medicine Technology: